1190-53-0
1190-53-0 结构式
基本信息
盐酸丁二胍
盐酸丁双胍
丁福明盐酸盐
丁双胍盐酸盐
盐酸丁双胍 标准品
N-丁基双胍盐酸盐
盐酸丁二胍/盐酸丁福明
正丁基亚胺基二碳亚胺二酰胺盐酸盐
盐酸丁福明, 盐酸丁二胍, 盐酸丁双胍
Andere
Adebit
TideMol
Biforon
Sindiatil
PanforMin
Ziavetine
NSC528218
Aids126511
物理化学性质
安全数据
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-B2099A | 盐酸丁双胍 Buformin hydrochloride | 1190-53-0 | 50 mg | 407元 |
| 2025/05/22 | HY-B2099A | 盐酸丁双胍 Buformin hydrochloride | 1190-53-0 | 10 mM * 1 mLin DMSO | 447元 |
| 2025/05/22 | HY-B2099A | 盐酸丁双胍 Buformin hydrochloride | 1190-53-0 | 100mg | 701元 |
常见问题列表
Buformin hydrochloride (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC 50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively.Buformin hydrochloride (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells.Buformin hydrochloride (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.
Cell Viability Assay
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM |
| Incubation Time: | 5 days |
| Result: | Reduced cell viability in erbB-2-overexpressing breast cells. |
Cell Cycle Analysis
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0.5 mM; 1 mM; 3 mM |
| Incubation Time: | 48 hours |
| Result: | Increased cells arresting in G0/G1 phase. |
Western Blot Analysis
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM |
| Incubation Time: | 24 hours |
| Result: | Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner. |
Buformin hydrochloride (oral administation; 7.6 mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice.
| Animal Model: | Female MMTV-erbB-2 transgenic mice |
| Dosage: | 7.6 mmol/kg |
| Administration: | Oral administation; 7 days |
| Result: | Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. |